Titulaer Maarten J, Verschuuren Jan J G M
Department of Neurology, K5-Q, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands.
Ann N Y Acad Sci. 2008;1132:129-34. doi: 10.1196/annals.1405.030.
Half the patients with Lambert-Eaton myasthenic syndrome (LEMS) have a small cell lung carcinoma (SCLC). SCLC is an aggressive tumor and survival is poor. We studied the differences between LEMS patients with and without an SCLC. Several items were identified, among which are age, smoking behavior, sex, the progression of clinical symptoms, HLA, and presence of Sox1 serum antibodies. The relationship between these parameters is not fully elucidated. Data support a role for the LEMS-related immune response in suppressing the tumor activity. We summarize the literature and present data from our Dutch cohort of 104 LEMS patients to compare the clinical and laboratory characteristics of tumor and nontumor related LEMS patients.
半数兰伯特-伊顿肌无力综合征（LEMS）患者患有小细胞肺癌（SCLC）。SCLC是一种侵袭性肿瘤，生存率较低。我们研究了合并和未合并SCLC的LEMS患者之间的差异。确定了几个项目，其中包括年龄、吸烟行为、性别、临床症状进展、HLA以及Sox1血清抗体的存在情况。这些参数之间的关系尚未完全阐明。数据支持LEMS相关免疫反应在抑制肿瘤活性中发挥作用。我们总结了文献，并展示了来自我们荷兰104例LEMS患者队列的数据，以比较肿瘤相关和非肿瘤相关LEMS患者的临床和实验室特征。
